Discovery of Innovative Therapeutics: Today's Realities and Tomorrow's Vision. 2. Pharma's Challenges and Their Commitment to Innovation

被引:29
作者
Abou-Gharbia, Magid [1 ]
Childers, Wayne E. [1 ]
机构
[1] Temple Univ, Sch Pharm, Moulder Ctr Drug Discovery Res, Philadelphia, PA 19140 USA
关键词
RESEARCH-AND-DEVELOPMENT; PNEUMOCOCCAL CONJUGATE VACCINE; POSITRON-EMISSION-TOMOGRAPHY; DRUG DISCOVERY; PHARMACEUTICAL INNOVATION; PERSONALIZED MEDICINE; ANTAGONIST APREPITANT; PARKINSONS-DISEASE; LIGAND EFFICIENCY; PROSTATE-CANCER;
D O I
10.1021/jm401564r
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The pharmaceutical industry is facing enormous challenges, including reduced efficiency, stagnant success rate, patent expirations for key drugs, fierce price competition from generics, high regulatory hurdles, and the industry's perceived tarnished image. Pharma has responded by embarking on a range of initiatives. Other sectors, including NIH, have also responded. Academic drug discovery groups have appeared to support the transition of innovative academic discoveries and ideas into attractive drug discovery opportunities. Part 1 of this two-part series discussed the criticisms that have been leveled at the pharmaceutical industry over the past 3 decades and summarized the supporting data for and against these criticisms. This second installment will focus on the current challenges facing the pharmaceutical industry and Pharma's responses, focusing on the industry's changing perspective and new business models for coping with the loss of talent and declining clinical pipelines as well as presenting some examples of recent drug discovery successes.
引用
收藏
页码:5525 / 5553
页数:29
相关论文
共 149 条
[41]  
Davis P. J., 2012, ACCENTURE LIFE SCI
[42]  
Day M, 2009, ADV EXP MED BIOL, V655, P1, DOI 10.1007/978-1-4419-1132-2_1
[43]   Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor [J].
Deecher, Darlene C. ;
Beyer, Chad E. ;
Johnston, Grace ;
Bray, Jenifer ;
Shah, S. ;
Abou-Gharbia, M. ;
Andree, Terrance H. .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 318 (02) :657-665
[44]  
Dinleyici EC, 2009, EXPERT REV VACCINES, V8, P977, DOI [10.1586/erv.09.68, 10.1586/ERV.09.68]
[45]  
Dykstra K., 2009, PHARSIGHT
[46]   Current development of mTOR inhibitors as anticancer agents [J].
Faivre, Sandrine ;
Kroemer, Guido ;
Raymond, Eric .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (08) :671-688
[47]   Lessons from 54 years of pharmaceutical research [J].
Firestone, Raymond A. .
NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (12) :963-963
[48]   Clinical biomarkers in drug discovery and development [J].
Frank, R ;
Hargreaves, R .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (07) :566-580
[49]   US academic drug discovery [J].
Frye, Stephen ;
Crosby, Marina ;
Edwards, Teresa ;
Juliano, Rudolph .
NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (06) :409-410
[50]  
Getz K., 2012, CONTRACT PHARM, V14, P54